According to the latest research report titled ‘Percutaneous Coronary Intervention (PCI) Devices Market Share, Size, Trends, Industry Analysis Report, By Product; By End Use; By Regions; Segment Forecast, 2020 -2027’, available with Market Study Report, global percutaneous coronary intervention (PCI) devices market valuation is projected to surpass USD 11.4 billion by the end of the forecast period 2020-2027.
 

Industry experts cite that burgeoning cases of cardiovascular ailments, particularly coronary artery disease (CAD), is driving global percutaneous coronary intervention (PCI) devices market growth. Increased risk of acquiring such diseases due to sedentary lifestyle, obesity, increased intake of smoking and alcohol, and hereditary factors are expanding the overall industry size.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2963823/
 

Further, technological advancements in stent technologies such as next-fen coronary catheters (percutaneous transluminal angioplasty (PTA) balloon catheters, percutaneous transluminal coronary angioplasty (PTCA)), and availability of coronary guide wires (nitinol based, steel based) have increased the treatment scope of coronary heart diseases.
 

Based on end-use spectrum, global percutaneous coronary intervention (PCI) devices market share from catherization labs is expected to increase substantially in the forthcoming years. This can be ascribed to establishment of dedicated catheterization labs in high income countries. Moreover, next-gen Caths labs offer several advanced services and interventional therapeutic procedures, as well as interventional cardiac electrophysiological procedures, cardiac defibrillator implantation, and pacemaker implantation.
 

Global percutaneous coronary intervention (PCI) devices market from hospitals segment is also witnessing a strong growth creditable to increasing efforts of governments and private hospitals towards setting up Caths labs for better service offerings. Conversion of physician’s office to alternate hospital providers, increasing collaboration between surgeons and manufacturers to eliminate dependency on general practitioner officers, and expansions of hospital service offerings are fostering the segmental growth.
 

With respect to competitive arena, Meril Lifesciences Pvt. Ltd., Medtronic plc, Comed B.V., C. R. Bard, Inc., Boston Scientific Corp., Biotronik, Inc., Biosensors International Ltd., B. Braun, Asahi Intecc Co., Ltd., and Abbott laboratories are the top contenders in global percutaneous coronary intervention (PCI) devices industry sphere. These industry behemoths are heavily investing in R&D, and are focused on launching new technologies & products to stay ahead of the competition.